Pharmaceutical giant Pfizer Inc. and BionTech SE made an exciting joint announcement on Monday that may help to relieve some of the anxiety over coronavirus. Two of the company’s four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) that are being developed to help protect against SARS-CoV-2 (the virus that causes … Continue reading “Pfizer and BioNtech Are Granted FDA Fast Track Designation for SARS-COV-2 Vaccine Candidates”
